GL
TLSI icon

Graypoint LLC’s TriSalus Life Sciences TLSI Stock Holding History

Graypoint LLC’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$656K Hold
120,355
– – 0.04% 280
2025
Q1 		$664K Hold
120,355
– – 0.04% 269
2024
Q4 		$603K Buy
+120,355
New +$509K 0.04% 270

Other funds holding TLSI

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graypoint LLC's TLSI Position: Q2 2025 in Review

Graypoint LLC held its TriSalus Life Sciences (TLSI) position steady in Q2 2025 at 120,355 shares worth $656K. The position accounts for 0.04% of the portfolio, ranked #280.

Graypoint LLC first reported a position in TLSI in Q4 2024 and has held it in 3 quarters since. The position peaked at $664K in Q1 2025. 48 funds tracked by Wall St. Rank hold TLSI as of Q2 2025.

  • Graypoint LLC held 120,355 shares of TriSalus Life Sciences worth $656K as of Q2 2025.
  • Graypoint LLC left its TriSalus Life Sciences share count unchanged in Q2 2025.
  • TriSalus Life Sciences made up 0.04% of Graypoint LLC's portfolio in Q2 2025, its #280 holding.
  • Graypoint LLC first reported a position in TriSalus Life Sciences in Q4 2024 and has held it in 3 quarters since.
  • Graypoint LLC's TriSalus Life Sciences position peaked at $664K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.